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Abstract: Background: Many of the activities associated with pepper fruits have been attributed to piperine, the 
most active compound present in these spices. 
Objective: This paper aims to provide an overview of the known properties of piperine, i.e. piperine’s chemistry, 
its physiological activity, documented interactions as a bioenhancer and reported data concerning its toxicity, 
antioxidant properties and anticancer activity. 
Discussion: It is known that piperine possesses several properties. In its interaction with other drugs, it can act as 
a bioavailability enhancer; this effect is also manifested in combination with other nutraceuticals, e.g. with cur-
cumin, i.e. piperine can modify curcumin’s antioxidant, anti-inflammatory, antimicrobial and anticancer effects. 
Piperine displays significant immunomodulating, antioxidant, chemopreventive and anticancer activity; these 
effects have been shown to be dose-dependent and tissue-specific. However, the main limitation associated with 
piperine seems to be its low bioavailability, a disadvantage that innovative formulations are overcoming. 
Conclusion: It is predicted that an increasing number of studies will focus on piperine, especially those directed 
towards unraveling its properties at molecular level. The current knowledge about the action of piperine will form 
a foundation for ways to improve piperine’s bioavailability e.g. exploitation of different carrier systems. The 
therapeutical applications of this compound will be clarified, and piperine will be recognized as an important 
nutraceutical. 
Keywords: Piperine, nutraceutical, characteristics, interactions, enhancer, antioxidant, anticancer. 
1. INTRODUCTION 
1.1. Nutraceuticals: An Overview 
 The link between diet and health has been known since ancient 
times. Hippocrates wrote about 2500 years ago “Let food be thy 
medicine and medicine be thy food”; this continues to be relevant 
today [1]. However, with the advancement of food science and 
nutrition, the role of diet has changed from simply preventing nutri-
tional deficiencies in  promoting optimal well-being and improving 
the quality of human life [2].  
 For example, the prolongation in lifespan has increased interest 
in the role of diet in the prevention of age- related chronic diseases 
as well as reducing healthcare costs [3]. 
 In the mid-1980s, the concept of functional foods was devel-
oped [4]. These are foods which when consumed as a part of a 
regular diet, may exert beneficial effects, e.g. they may act on one 
or more targets or functions [5]. Similarly, some types of unmodi-
fied whole, processed, enhanced or fortified food can be considered 
as functional foods [6]. Several years later, Dr. De Felice intro-
duced the term “nutraceutical” as “a food or part of a food that 
provides medicinal and health benefits, including the prevention 
and/or treatment of a disease” [7]. At present, in the absence of 
clear and universally accepted definitions, there is an overlap be-
tween nutraceuticals and functional food, and this passes over to 
other health-related food products [8]. Therefore, in addition to 
nutraceuticals, dietary supplements can also be viewed as functional 
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[9]. These products represent concentrated forms of natural bioac-
tive substances in a suitable pharmaceutical form but they are used 
in dosages that exceed those that can be obtained from a regular 
diet [10]. 
 In addition to nutrients such as vitamins, minerals, amino acids, 
peptides, and some fatty acids, there are other specific bioactive 
compounds that can be considered as nutraceuticals: enzymes, pre- 
and probiotics, coenzyme Q10, glucosamine, chondroitin, etc., as 
well as many phytochemicals (polyphenols, sulfur-containing com-
pounds, alkaloids, terpenoids etc.) [11, 12]. There are several ways 
to classify nutraceuticals i.e. based on the bioactive compounds 
present [3, 13, 14] and their functions [3, 9]; according to their 
origin [1, 3, 8, 9]; their concentrated sources [1, 9]; mechanisms of 
actions and health benefits [1, 3, 14, 15] or their chemical nature [1, 
9, 15]. Nutraceutical classifications can also be based on nutraceuti-
cal bioaccessibility, absorption, or chemical transformation within 
the gastrointestinal tract, as these can be factors limiting their oral 
bioavailability [16]. Additionally, nutraceuticals can be classified 
into potential and/or established nutraceuticals according to their 
proven beneficial effects as demonstrated in either preclinical or 
clinical studies [17]. At present, only probiotics, prebiotics, omega-
3 acids, and antioxidants have been placed in the category of estab-
lished nutraceuticals [18]. Therefore, it is evident that problems are 
encountered in classifying nutraceuticals, i.e. one substance can be 
placed into one or more categories. Table 1 lists several nutraceuti-
cals categorized according to their chemical and biological proper-
ties [11, 13, 14, 19]. 
 In addition to their sensory properties, the herbs and spices in 
our diet are rich sources of different phytochemicals with putative 
beneficial effects e.g. antioxidative, anti-inflammatory, chemopre-
ventive, antimutagenic, immune-modulatory properties [20-22]. 
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Due to their potent biological activities and low or non- existent 
side effects, some of these phytochemicals are being investigated in 
preclinical and clinical trials as a new approach to treating diseases 
[23, 24] or as lead compounds in the design of innovative drugs 
[25]. Moreover, there is evidence that some phytochemicals can 
enhance the bioefficacy of drugs like antimicrobials, antihyperten-
sives, anticancer drugs, and improve the bioavailability of some 
nutraceuticals [26, 27]. Due to their natural origin, ease of access, 
cost-effectiveness and satisfactory safety profiles, these kinds of 
nutraceuticals have attracted the attention of scientists, consumers, 
and commercial enterprises [28]. 
1.2. Piperine as a Nutraceutical 
 Piperine (E,E)-1-piperoylpiperidine or (E,E)-1-[5-(1,3-
benzodioxol-5-yl)-1-oxo-2,4 pentdienyl]-piperidine is an alkaloid 
present in the piper species, the fruit of black pepper (Piper nigrum 
Linn.) and long pepper (Piper longum Linn.). Piperine has been 
used in traditional medicine for a long time, in treatment of various 
conditions: rheumatism and muscular aches, as a digestive tonic, in 
dyspepsia, in flatulence and indigestion, as antipyretic, for throat 
pain and cough; as antiseptic, bactericide, insecticide, diuretic, etc. 
[29]. In addition to its traditional use, crucial non-traditional nu-
traceutical effects have been proposed for piperine, based on cell-
based studies, animal studies and human studies, reviewed in sev-
eral articles [26, 29-36]. For example, piperine increases the 
bioavailability of several drugs from 30 up to 200 fold; for curcu-
min, this enhancing ability was almost 9-10 fold [37, 38].  
 Piperine is a molecule that is a promising nutraceutical, with 
some of its potential uses represented in Fig. (1). Moreover, its 
structure is especially suitable for chemical modifications and al-
terations, it can present an advantage in the development of novel 
compounds with various health protective activities. 
2. CHEMICAL AND PHYSIOLOGICAL CHARACTERIS-
TICS OF PIPERINE 
2.1. Chemistry of Piperine and its Importance for the Com-
pound’s Mechanism of Action 
 The piperine type of amides are a group of alkaloids; their bio-
genesis is initiated by the pyridoxal-phosphate catalyzed decar-
boxylation of L-lysine to cadaverine, which undergoes an enzy-
matic oxidative deamination to amino aldehyde which cyclizes to 
the imine form Δ1-piperideine, followed by a reduction of 
piperidine which reacts with piperoil-Co-A (piperic acid-coenzyme 
A ester) forming a piperine [39]. 
 Piperine, accounting for around 98% of the total amount of 
alkaloids in black pepper, is the most abundant pungent alkaloid; it 
is responsible for the pungency of pepper. Single crystal X-ray 
diffraction and mass spectroscopic analysis of yellow prism-like 
crystal revealed a melting point in the range 128-130 °C. The crys-
tal and molecular structure of piperine (1-piperoylpiperidine) has 
been discovered after recrystallisation from ethanol oleoresin ex-
tract of black pepper, i.e. the molecular formula of C17H19O3N and 
a molecular mass of 285.1365. It has been revealed that piperine is 
ternary type of amide which is formed between piperidine in the 
chair conformation and piperic acid (5-(3,4-methylenedioxy-
phenyl)-2,4-pentadienoic acid) [40].  
 Four geometric isomers of piperine, represented in Fig. (2), 
have been characterized: The major component piperine (trans-
trans isomer), isopiperine (cis-trans isomer), chavicine (cis-cis 
isomer), and isochavicine (trans-cis isomer), the last three forms do 
Table 1. Classification of nutraceuticals. 
Nutraceuticals 
According to Chemical Composition 
According to Effects Against a  
Specific Disease 
Nutrients 
(chemical substances with 
established nutritional 
functions) 
Herbs* 
(herbs and herb parts as concentrates, ex-
tracts…) 
Dietary supplements 
(products - tablets, capsules, liquids, powders, 
etc., administered orally to enrich the diet) 
Vitamin A 
Complex B vitamins (B1, 
B2, B3, B6) 
Vitamin C  
Vitamin K  
Folic acid 
Minerals (Ca, Fe, Mg, P, 
Cr, Co, Cu, Zn, I) 
Amino acids  
Fatty acids 
Aloe (Aloe vera L.)  
Garlic (Allium sativum L.) 
Curcumin (Curcuma longa)  
Green tea (Camelia sinensis) 
Echinacea (Echinacea purpurea L.)  
Ginkgo (Ginkgo biloba L.) 
St. John’s wort (Hypericum perforatum L.)  
Chamomile (Matricaria recutita L.)  
Melissa (Melissa officinalis L.) 
Ginseng (Panax ginseng)  
Black pepper (Piper nigrum) 
Valerian (Valeriana oficinalis L.)  
Ginger (Zingiber officinale Rosc.) 
Ingredients incorporated into ketogenic diets 
(e.g. coenzyme Q10) 
Dietary fibers 
Phytoestrogens 
Different species of edible mushrooms (mush-
room beta- glucans or mushroom polysaccha-
rides) 
Glucosamine sulfate  
Chondroitin sulfate  
Peptides and hydrolysates  
Probiotics 
Carotenoids (e.g. lycopene, lutein) 
Unsaturated fatty acids (e.g. EPA, DHA, CLA) 
Cardiovascular protective agents 
Antidiabetic agents 
Antiobesity agents 
Anticancer agents 
Antidepressive agents 
Agents that improve vision 
Agents with effects on osteoarthri-
tis and other conditions affecting 
the musculoskeletal system 
*Selection has been based on the most frequent use (adapted with modifications from [11, 13, 14, 19]). 
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not possess any pungent properties [36]. The rate and degree of 
isomerization are variable. After oral ingestion of piperine in doses 
of 50 mg, no isomers other than piperine were detected in human 
plasma (healthy volunteers) [41, 42]. Piperine is a weak base that 
undergoes hydrolysis and has a limited solubility in water (only 40 
mg/L at 18°C) [43]. This is a challenge, but it may be possible to 
overcome these limitations with nano-scaled formulations for poly-
phased delivery systems (e.g. solid dispersions, solutions, capsu-
lated vesicles and particles) as well as advanced energy-efficient 
and environmentally friendly extraction technologies (e.g. super-
critical fluid extraction, ultrasound and microwave- assisted extrac-
tions) [36]. The combination of Accelerated Solvent Extraction 
(ASE) of piperine and its quantification by thin layer chromatogra-
phy (TLC) has proved to be an efficient, precise, accurate and cost- 
friendly analytical technique for the rapid screening of the quality 
of these kinds of spices [44]. 
 The production of molecular salts of piperine with highly water 
soluble counter ions, offers an opportunity for increasing the water 
solubility of piperine i.e. these modifications affect its absorption 
rate and enhance its bioavailability. A recent study on non-covalent 
interactions between piperine and native β-cyclodextrin underlined 
the increased water solubility of piperine due to the formation of a 
piperine-β-cyclodextrin inclusion complex in solution [45]. 
 The native form of the piperidine molecule inhibits UDP-
glucose dehydrogenases [46] and specific dehydrogenase com-
plexes associated with the electron transport chain [47]. An assess-
ment of the structure- activity relationship of 38 modified piperine 
derivatives revealed that the degree of saturation of the unsaturated 
double bonds in the side chain of the piperidine molecule correlates 
with enhanced inhibition of rat hepatic constitutive and inducible 
cytochrome P450 (CYP450) activities. Furthermore, it has been 
demonstrated that the substituted methylenedioxyphenyl ring and 
basic piperidine ring contribute to their maximal selectivity [48]. 
Therefore, these synthetic piperine analogues may be useful in 
modifying the bioavailability. 
 Fluorescence titration measurements of two different binding 
constants of piperine complex with human G-quadruplex DNA 
sequences correlate to affinity of piperine for two different binding 
sites. The highest value is a result of the binding of piperine with 
Pu24T c-myc G-quadruplex DNA as compared to other G-
quadruplex DNA i.e. differences in sequences and topology lead to 
reduced affinity in the specific binding in the formation of piperine-
DNA complexes [49].  
2.2. Absorption and Metabolism of Piperine 
 The findings regarding the absorption and metabolism of piper-
ine in humans have largely originated from animal studies. In one 
of the first investigations of piperine metabolism, piperine was 
administered to male albino rats (170 mg/kg) by gavage and around 
97% was found to be absorbed. Approximately 3% of the adminis-
tered dose of piperine was excreted in the feces, while levels in 
urine were undetectable, indicating its complete metabolic conver-
sion [50]. Piperine was absorbed very rapidly through the intestinal 
barrier [51]. After intestinal absorption, due to its insolubility in 
water, serum albumin is proposed to be the main carrier in its trans-
portation in blood [52]. However, in serum only traces of piperine 
(< 0.15 %) from 30 min to 24 h after administration were detected, 
which implies its very low bioavailability and intensive intestinal 
Fig. (1). Potential uses of piperine as nutraceutical. 
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Fig. (2). Geometric isomers of piperine. 
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metabolism. The main routes of Phase II metabolism of piperine are 
glucuronidation and sulpha-conjugation. After oral administration 
of piperine (in rats), the following main metabolites were detected 
in urine, at 0-96 h after administration: piperonylic acid, piperonyl 
alcohol, piperonal, and vanillic acid; at 0-6 h after administration, 
piperic acid could be detected in bile, but no metabolites could be 
determined in feces [31, 50]. One human study revealed that after 
intake of piperine capsules (20 mg) for 7 days, piperine did not 
accumulate in healthy volunteers [53].  
2.3. Toxicological Data on Piperine 
 Piperine can be present in human diet as natural ingredient of 
black pepper or can be added to food and drink as flavouring agent 
in different concentrations which can vary extensively, from 0.4-6 
ppm (in candies) to 640 ppm (in some baked products) [54]. Re-
garding the fact that oleoresin of black pepper consists of 40% 
piperine, individual human exposure to piperine is estimated based 
on black pepper consumption and is around 1 pg/kg/day [55]. Based 
on these data, and the fact that piperine is more irritant rather than 
toxic, its intake from regular food raised no safety concern. No 
observed adverse effect level (NOAEL) of piperine is 5 mg/kg daily 
[56].  
 The pharmaceutical use of piperine is limited due to its low 
water solubility of only 40 mg/L at 18 °C [43] and putative toxicity 
(immunotoxicity, reproductive and neurotoxicity) at high concen-
trations [57, 58]. The different toxicity aspects of piperine have 
been evaluated in the past years. LD50 of piperine in mice and rats 
is estimated to be 330 and 514 mg/kg, respectively. Doses of 100 
mg/kg were found to be nontoxic in subacute toxicity tests [59]. 
Piperine has been claimed to be a non-genotoxic chemical based on 
the results from four different types of genotoxicity tests (Ames 
test, micronucleus test, test for sperm shape abnormality and domi-
nant lethal test) [60-63]. Furthermore, piperine was observed to 
exert a suppressive effect on the micronucleus formation induced 
by benzo(a)pyrene and cyclophosphamide in mice [64, 65]. In addi-
tion, there are studies where the antigenotoxic effects of piperine 
(provided as a feed additive) against the toxicity of aflatoxin B1 
have been analyzed and it was proposed as being safe with respect 
to its protective role against aflatoxin-genotoxic action [66]. 
 The immunotoxicity of piperine has been investigated in Swiss 
male mice where doses of 1.12, 2.25 or 4.5 mg/kg were adminis-
tered [67]; piperine was assessed to be an immunologically safe 
compound. Furthermore, piperine was found to possess immuno-
modulatory properties and to confer protection against the immuno-
toxicity evoked by different agents, for example, cadmium [68, 69], 
cypermethrin [70] or deltamethrin [71]. In these studies, piperine 
has been claimed to be an effective agent in reducing the adverse 
effects of immunotoxins on apoptosis, blastogenesis, T- and B-cell 
phenotypes differentiation and cytokine production. Piperine con-
tains a pentacyclic oxindole group in its molecule, which might be 
related to its possible immunomodulatory properties. 
 With regard to reproductive toxicity, the majority of studies 
have been conducted on experimental animals, most usually in rats 
or Swiss albino mice, i.e. a short-term toxicity test was employed 
for assessing piperine’s effects on estrous cycle, spermatogenesis, 
fertilization, male germ cell, epididymis enzymes, etc. Doses up to 
75 mg/kg did not induce abnormalities, while at higher doses (100 
mg/kg) reductions were observed in the activity of enzymes and 
sialic acid levels in the epididymis as well as in testis development 
in pubertal rats [72-74]. 
3. INTERACTIONS OF PIPERINE WITH OTHER COM-
POUNDS 
3.1. Piperine-drug Interactions 
 Beside regular dietary sources, piperine is an ingredient of nu-
merous marketed herbal medicines and food supplements. Excess 
intake of these products, that provide more than 10 mg of piperine, 
might result in clinically significant interactions with several drugs 
[75]. As such, piperine can have a great impact on the bioavailabil-
ity and pharmacokinetics of other co-administered drugs by modu-
lating their intestinal absorption and metabolism. 
 There are two possible pathways for nonspecific piperine-drug 
interactions:  
(1) Promoting more efficient absorption of drugs (or some nutri-
ents) by prevention of their non-enzymatic breakdown (de-
creased secretion of HCl in the stomach) or promotion of ac-
tive and passive transport mechanisms in the intestine, and  
(2) Interaction mechanisms where piperine inhibits drug-
metabolising enzymes thus preventing the drug’s inactivation 
and elimination [26, 33, 76]. 
 It has been reported that piperine induces alterations in the vil-
lus-crypt structure that alter its fluidity as well as evoking changes 
in the conformation and activity of enzymes on the outer intestinal 
membrane. Another possibility to explain piperine’s bioenhancing 
properties is that it changes gastric emptying and transit time to 
allow increased drug absorption [33, 77-80]. 
 Piperine has been shown to inhibit both in vivo and in vitro 
drug-metabolizing enzymes and drug-transporter proteins in a non-
specific manner [31, 81-84]. However, it has also been observed to 
exert stimulating effects on the activity/expression of some en-
zymes (mainly those in the CYP family) depending on the route, 
dose and time of piperine exposure [85, 86]. Piperine has been re-
ported to inhibit many important detoxifying enzymes e.g. cyto-
chrome P450 family (mainly CYP3A4, also CYP1A1, CYP 
1B1/B2, CYP2E1, etc.), aryl hydrocarbon hydroxylase (AHH), 
ethyl morphine-N demethylase, 7-ethoxycoumarin-O-de-ethylase, 
3-hydroxy- benzo[a]pyrene glucuronidase, uridine diphosphate 
glucose dehydrogenase (UDP-GDH), uridine diphosphate glucuro-
nyl transferase (UDP-GT), 5-lipoxogenase (5-LOX), cyclooxy-
genase-I (COX-I). The majority of drugs available today are me-
tabolized by CYP enzymes (e.g., CYP3A4) and UGT, thus studies 
of possible interactions with piperine have mainly focused on these 
entities [80, 87, 88]. 
 The inhibitory effects of piperine on the activity and expression 
of drug-transporter proteins have been investigated mainly with 
transporters belonging to ATP-binding cassette (ABC) family, like 
P-glycoprotein (P-gp) [89]. Piperine modulates the activity and 
expression of P-gp. This interaction is currently a subject of great 
research interest because of putative alterations of the pharmacoki-
netic profile and consequent adverse effects of P-gp substrate drugs 
on one hand, and on the other, the possible beneficial effects in 
cancer treatment. For example, piperine may enhance the cytotoxic-
ity of anticancer drugs or reverse multidrug resistance in a dose-
dependent manner [80]. Beside anticancer agents, there are differ-
ent classes of drugs, which may interact with piperine: carvedilol, 
diclofenac, fluvastatin, glimepiride, glipizide, ibuprofen, losartan, 
naproxen, rosiglitazone, valproic acid; all of them are listed in 
DrugBank database (www.drugbank.ca/drugs/DB12582). 
3.2. Interactions of Piperine with other Nutraceuticals: Focus 
on Curcumin 
 Curcumin is a popular and widely investigated nutraceutical, 
since it exerts antioxidant, anti-inflammatory, antimicrobial and 
anticancer effects. However, this natural polyphenol has limited 
therapeutic potential due to its poor bioavailability i.e. its limited 
aqueous solubility, poor absorption, extensive metabolism in liver 
and intestine, as well as its rapid elimination (for a review see 
Hewlings and Kalman, 2017, [90]). Piperine has been postulated to 
overcome the pharmacokinetic drawbacks of curcuminoids like 
curcumin e.g. it was reported to increase its bioavailability up to 
2000% in humans [91]. Piperine enhances the absorption of curcu-
minoids by reducing the activity of glucuronidase both in intestine 
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and the liver, and by increasing intestinal perfusion [91]. There are 
a number of convincing reports providing clear evidence that co-
administration of curcumin with piperine maximizes its antioxidant, 
anti-inflammatory effects thus conferring protection against a vari-
ety of diseases. In a recent double-blind placebo-controlled study in 
type 2 diabetes patients, co-supplementation of curcumin with 
piperine (1000 and 10 mg/day respectively) for 8 weeks led to an 
enhanced antioxidant capacity as reflected in an elevated serum 
total antioxidant capacity (TAC), increased activity of superoxide 
dismutase (SOD) and lowered levels of lipid peroxidation [92]. 
Consistently, in a randomized double-blind placebo-controlled trial 
in subjects with the metabolic syndrome (MetS), 8-week supple-
mentation of curcumin (1 g/day) with piperine (10 mg/day) de-
creased lipid peroxidation and induced SOD activity. Furthermore, 
in the same study, curcumin and piperine co-supplementation ex-
erted an anti-inflammatory effect as evidenced by a decrease in hs-
CRP; it also improved glucose metabolism as revealed by a de-
crease in HbA1c levels [93]. Increased oxidative stress and inflam-
mation are emerging components of the pathogenesis of exercise-
induced muscle damage. The protective role of curcumin and piper-
ine against exercise-induced muscle damage was explored recently 
in elite rugby players. Daily supplementation with 6 g of curcumin 
and 60 mg of piperine between 48 h before and 48 h after acute 
exercise partly attenuated markers of muscle damage and soreness 
[94]. Among the existing strategies to enhance the bioavailability 
and antioxidant properties of curcumin, co-administration of cur-
cumin and piperine together with quercetin have been claimed to be 
potentially beneficial. A combination treatment consisting of cur-
cumin with piperine and quercetin was able to combat impaired 
SOD and glutathione peroxidase activities, and the reduced glu-
tathione levels evoked by consumption of a high-fat diet or strepto-
zotocin-induced diabetes in rats [95]. Nonetheless, in contrast to 
these reports, treatment of curcumin with 20 mg/kg piperine to rats 
with experimentally-induced diabetes did not further improve an-
tidiabetic and antioxidant effects of curcumin; in fact, co-
supplementation of piperine at a 40 mg/kg dose abolished the bene-
ficial effects of curcumin [96]. 
 Synergistic interactions of piperine with other nutraceuticals 
have been reported [26]. In a recent study, four weeks of co-
supplementation of resveratrol with piperine potentiated efficiency 
of low-intensity exercise training on skeletal muscle mitochondrial 
capacity in healthy young adults [97]. Similarly, compared to single 
resveratrol supplementation alone, a co-supplementation with piper-
ine increased the bioavailability of resveratrol by 229% and de-
creased its metabolites approximately 80% [98]. This bioenhancing 
effect was attributed to inhibiting glucuronidation, and slowing 
down the elimination of resveratrol by piperine [98]. Moreover, 
earlier human studies demonstrated that oral supplementation of 
piperine increased gastrointestinal absorption of beta carotene [99] 
and elevated plasma levels of co-enzyme Q10 [100]. 
4. RECENT THERAPEUTIC INSIGHTS OF PIPERINE AS 
ANTICANCER AGENT: THE IMPORTANCE OF ANTI-
OXIDANT POTENTIAL  
 Oxidative stress, a state of imbalance between the generation of 
reactive oxygen species (ROS) and the antioxidant defense capacity 
of the organism, is nowadays known to be involved in many disease 
processes including cancer, but also atherosclerosis, inflammation, 
ageing, etc. [101-103]. Indeed, high concentrations of ROS are 
harmful to the organism since they can damage all of the major 
cellular constituents e.g. evoking lipid-, DNA-, protein oxidation 
resulting in protein misfolding and aggregation [104]. In contrast, at 
moderate concentrations, ROS play an important role in cellular 
signaling and are essential in physiological homeostasis. Therefore, 
increased ROS production during times of increased oxidative 
stress can disrupt redox regulation of cellular processes [105]. In 
biological systems, there is a kind of orchestrated synergism, in 
which a variety of endogenous and dietary antioxidants detoxifies 
ROS, to combat oxidative stress and maintain redox control [106]. 
 The health benefits of piperine have been attributed to its possi-
ble antioxidant properties and inhibitory effects on the production 
of ROS (see for a review of Srinivasan, 2014) [107]. Earlier studies 
demonstrated that piperine was a potent inhibitor of oxidative dam-
age capable of preventing lipid peroxidation in vitro [108]. Fur-
thermore, piperine inhibited copper-induced lipid peroxidation of 
human low density lipoprotein (LDL) as reflected in a decrease in 
the level of thiobarbituric acid reactive substance (TBARS) and 
relative electrophoretic mobility (REM) of LDL on agarose gel 
[109]. However, at equimolar concentrations, the inhibitory effect 
of piperine on oxidation of LDL was less potent than the other 
compounds studied i.e. curcumin, quercetin and capsaicin [109]. 
Nonetheless, piperine supplementation (0.02 g/kg body weight) for 
10 weeks counteracted to a significant extent the increased lipid 
peroxidation and impaired antioxidant enzyme activities and re-
duced glutathione (GSH) levels in rats fed a high-fat diet [29]. The 
protective role of piperine against oxidative stress was confirmed in 
a recent study, in which piperine at concentrations of 35 and 50 µM 
improved lipid peroxidation and prevented DNA damage in a cad-
mium-induced model of oxidative stress in peripheral blood lym-
phocytes obtained from healthy individuals [110]. 
 The impact of low dose and short term piperine treatment (10 
mg/kg/day, intraperitoneally for 14 days) has been investigated in 
various tissues of rats with streptozotocin-induced diabetes (SID). 
Treatment with piperine reversed the SID-induced disruptions in 
oxidative stress and antioxidant defense markers in a tissue-specific 
manner [111]. Piperine treatment counteracted SID-induced oxida-
tive stress as reflected in the increased oxidized glutathione (GSSG) 
levels in the brain and the prevention of lipid peroxidation in heart 
tissue. In addition, piperine supplementation restored the reduced 
activities of glutathione peroxidase (GSHPx) and SOD in kidney 
tissue and glutathione reductase in heart tissue. On the other hand, 
in liver tissue, piperine supplementation did not prevent oxidative 
stress or reverse the impaired antioxidant defense in SID rats. In 
fact, it even induced oxidative stress in non-diabetic animals i.e. 
there was an increase in the glutathione oxidation ratio [111]. In 
another study employing the rat SID model, the effects of different 
doses of piperine treatment on oxidative stress and antioxidant 
markers were compared. Lower doses of piperine supplements (20 
mg/kg) for 45 days decreased markers of lipid peroxidation and 
protein oxidation and conversely increased the activities of three 
antioxidant enzymes SOD, GSHPx and catalase [96]. Notably 
lower doses of piperine supplementation enhanced GSH, which is 
an important endogenous antioxidant and a key redox regulator. 
Surprisingly, at higher piperine supplementation doses (40 mg/kg), 
these beneficial alterations in oxidative stress markers and antioxi-
dant defense were largely abolished in the SID rats [96]. The same 
pattern of a dose-dependent dual action of piperine was observed in 
another study, i.e. at lower doses, piperine acted as a hydroxyl radi-
cal scavenger, but at higher concentrations, there was evidence of 
an activated Fenton reaction and increased production of hydroxyl 
radicals [108]. Nevertheless, a recent study demonstrated that in 
H661 cells, that have a very low background level of ROS produc-
tion, piperine treatment between 0.5-100 µM concentrations did not 
induce any ROS generation [112]. In addition, piperine displayed a 
moderate H2O2 scavenging effect and a minor inhibition of ROS 
production as revealed by attenuated NADPH oxidase (NOX) activ-
ity [112]. 
 These studies provide evidence that the antioxidant properties 
of piperine may be dose-dependent and tissue-specific. On the other 
hand, as far as we are aware, there are no human studies performed 
that uncover the role of sole supplementation of piperine on anti-
oxidant protection against oxidative stress. Nevertheless, several 
human studies revealed the bioenhancer role of piperine in combi-
nation with other antioxidant compounds [97-100]. Therefore, 
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piperine not only possesses antioxidant effects itself, but it can also 
potentiate the antioxidant effects of other nutraceuticals as summa-
rized in the previous section. 
 Piperine’s confirmed antioxidative effect could well be linked 
with chemoprevention. According to current theories, piperine 
could be effective as an anticancer agent, alone, or in combination 
with other anti-cancer agents. The mechanism of piperine antitumor 
effect might be related to its immunomodulatory properties [113], 
but many reports point out the importance of its antioxidant activity 
as well as its ability to inhibit the proliferation and survival of vari-
ous types of cancer cells. Other beneficial properties may be modu-
lation of redox homeostasis, induction of detoxification enzymes, 
inhibition of angiogenesis, and sensitization of tumors to radiother-
apy and chemotherapy [114, 115]. 
 There are many reports investigating the involvement of piper-
ine in combatting carcinogenesis. The effects of piperine on the 
procarcinogenesis arising from toxicity and genotoxicity induced by 
aflatoxin B1 have been investigated for several decades. In an early 
study, Singh and his collaborators (1994) demonstrated that piper-
ine could reduce the toxicity of aflatoxin B1, suppressing the toxic-
ity (activation) of the mycotoxin via the cytochrome p-450 path-
way. This conclusion was achieved using rat hepatoma cells 
H4IIEC3/G-(H4IIE) and analyzing cellular growth and the forma-
tion of micronuclei [116]. Later in 1997, Reen et al. reported that 
piperine was a potent inhibitor of rat CYP4502B1 activity; this 
prevented the CYP4502B1-mediated activation of aflatoxin B1 in 
these cells, i.e. it acted chemopreventive against the procarcino-
genesis mediated through this pathway [117]. Subsequently, 
Selvendiran and collaborators have examined the chemopreven-
tive/anticancer properties of piperine. They investigated the cyto-
protective effect of piperine after inducing an experimental lung 
cancer in male Swiss albino mice, using benzo[a]pyrene, a carcino-
gen known to cause lipid peroxidation. They monitored the level of 
lipid peroxidation and the status of several enzymatic antioxidants 
(SOD, catalase and glutathione peroxidase) and non-enzymatic 
antioxidants (reduced glutathione, vitamin E, and vitamin C) levels. 
They reported that piperine, when given by oral route at 100 mg/kg, 
enhanced the levels of both enzymatic and non-enzymatic antioxi-
dants and suppressed lipid peroxidation not only if the animals were 
treated with piperine prior to the induction of lung cancer, but also 
in those receiving piperine after the induction of the lung cancer. 
Since there was a more pronounced effect in pre-treated animals, it 
was postulated that piperine exerted chemopreventive effects [118]. 
In further investigations using the same model, a significant de-
crease in the levels of lipid peroxidation was observed [119, 120]. 
These investigators also revealed that levels of protein carbonyls, 
nucleic acid content and polyamines (i.e. factors known to be in-
creased in lung cancer-bearing animals), were lowered after piper-
ine administration. The ability of piperine to inhibit lung metastasis 
induced by administration of B16F-10 melanoma cells to C57BL/6 
mice was studied by Pradeep and Kuttan (2002). They reported that 
piperine was 100% cytotoxic to B16F-10 melanoma cells at a con-
centration of 100 µg/mL, while being nontoxic at a tenfold lower 
concentration. They also observed a significant reduction in lung 
tumor nodule formation (95.2%) when animals were treated with 
piperine (200 µmol/kg body weight/dose) simultaneously with the 
inoculation of the tumor cells in order to generate a metastatic dis-
ease. An increase in the life span of these mice was also noted as an 
outcome of piperine administration. After analyzing several other 
parameters, such as lung collagen hydroxyproline, lung uronic acid 
and hexosamine contents, serum sialic acid and serum gamma glu-
tamyl transpeptidase, they concluded that all these metastasis mark-
ers significantly declined in response to piperine administration 
[121]. 
 Bezeera et al. (2006), examined the potential of piperine and 
piplartine to inhibit Sarcoma 180 –initiated tumor growth in Swiss 
mice, comparing their activity with 5-fluorouracil (5-FU) treatment. 
A significant reduction in the tumor weight was observed with both 
administered doses (50 and 100 mg/kg), in piplartine- and piperine- 
treated animals; there was a tumor growth inhibition ratio of 55.0% 
and 56.8% for piperine, at doses of 50 and 100 mg/kg, respectively. 
At a dose of 25 mg/kg per day, 5-FU was observed to reduce tumor 
weight by 76.7%, over the same time frame [122]. The same group 
conducted a more extensive analysis of the effects of piperine and 
piplartine, but in combination with 5-FU. They undertook an in 
vitro test of inhibitory activity in four different tumor cell lines, 
HL-60, MDA-MB435, SF295 and HCT-8. They observed that the 
piplartine-5- FU combination exerted more potent in vitro cytotoxic 
effects than piperine-5-FU, although previously both substances 
were reported to have similar antitumor activities in vivo in the 
Sarcoma 180 model [123]. The antitumor action and immunomodu-
latory activities of piperine and alcoholic Piper longum extracts 
were examined by Sunila and Kuttan (2004). They reported that 
piperine alone evoked more potent cytotoxicity to Dalton’s lym-
phoma ascites cells than Piper longum alcoholic extract. They also 
observed an increase in the life span of Ehrlich ascites carcinoma 
bearing Swiss albino mice. Furthermore, the animals treated with 
the 1.14 mg intraperitoneal (i.p.) dose of piperine experienced a 
greater reduction in tumor growth than those receiving the i.p. 
alcoholic extract of Piper longum at a dose of 10 mg [113]. 
 During the current decade, the potential benefits of piperine 
have been examined in some detail. Lai et al. (2012), investigated 
the effects of piperine on tumor growth and metastasis in 4T1 
mammary carcinoma in female BALB/c mice. Piperine was in-
jected into the tumor mass every 3 days on 3 occasions. When in-
jected in two doses, 2.5 and 5 mg/kg piperine showed suppression 
of primary 4T1 tumor growth in dose-dependent manner. At the 
same time, administration of 5 mg/kg piperine was reported to sig-
nificantly inhibit the lung metastasis [124]. In an attempt to reveal 
the underlying mechanisms of piperine’s action, Hwang and his 
collaborators examined the effects of piperine at preventing tumor 
invasion and migration using human fibrosarcoma HT-1080 cells. 
Their study revealed piperine-mediated suppression of the expres-
sion of metalloproteinase-9 (MMP-9) at different levels, suggesting 
that piperine could possibly inhibit tumorigenesis [125]. The anti-
tumor properties of piperine have also been investigated in breast 
cancer cells by Do et al., (2013). They observed that piperine in-
duced growth inhibition and cytotoxicity through both caspase-3 
activation and PARP cleavage in several types of human breast 
cancer cells that were overexpressing HER2. The authors also con-
firmed the existence of the suppression of EGF-induced MMP-9 
expression. In addition, pretreatment with piperine enhanced the 
sensitization of HER2-overexpressing breast cancer cells to pacli-
taxel-induced growth inhibition and apoptosis [126]. 
 Further insights into the mechanism of action of piperine have 
revealed that it can bind to various human G- quadruplex DNA 
sequences. Tawani and collaborators reported that piperine’s anti-
cancer activity could be mediated through the stabilization of the G-
quadruplex structure formed at the c-myc promoter region of the 
DNA sequence (Pu24T), leading to a down-regulation of its expres-
sion in cancer cells [49]; this might be the mechanism behind piper-
ine’s anticancer activities observed in the above mentioned studies. 
5. CURRENT DEVELOPMENTS AND FUTURE PERSPEC-
TIVES 
 It is of no doubt that the antioxidative effect is the most ex-
ploited and most important property of piperine, especially concern-
ing its anticancer activity. However, recent research reveal that also 
the prooxidant activity of piperine, affecting redox state of cancer 
cells, might be relevant to its anticancer potential [127]. Namely, 
the increased oxidative stress results in extreme susceptibility of 
cancer cells to prooxidant agents that eventually make piperine 
selectively cytotoxic [115].  
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 A number of investigations have been and still are being per-
formed with a primary goal of defining the biological activities and 
possible health risks of black pepper and its active principle, piper-
ine. Clinical trials that include sole use of piperine in human sub-
jects are still missing. Nevertheless, evidences from animal studies 
support its non-toxicity if administered in moderate doses [128, 
129].   
 The main issues that today still limit the wider use of piperine 
in medical practice, specifically in combination therapy to exploit 
its bio-enhancer properties, are related to its low bioavailability and 
potential for drug interactions. These problems still need to be re-
solved and attention must be paid to the proper dose and dosing 
regimen, as well as to the design of suitable pharmaceutical formu-
lation(s) that will improve piperine’s in vivo effects. Currently, the 
major efforts to transfer piperine from basic research to clinical 
practice are focused on the development of formulations that im-
prove its low aqueous solubility and poor absorption. For example, 
one development has been the encapsulation of piperine in lipid 
carriers (e.g., liposomes), or its incorporation in nanoparticles [130-
137]. 
 Even though its mechanism of action has not been completely 
clarified, piperine is established as the first certified bioenhancer 
due to its ability to reduce the activity of certain enzymes (mainly 
CYP3A4) and to inhibit P-gp. In this respect, currently its main 
application in pharmaceutical formulations is as a bioavailability 
enhancer for different drugs and natural compounds in complex 
delivery systems. Combinations of piperine and drugs used to treat 
several major diseases, including tuberculosis, cardiovascular, neu-
rological, and gastrointestinal disorders, are being evaluated 
(www.drugbank.ca/drugs/DB12582). Since nowadays plant extracts 
are preferred as active agents, trials are being performed with novel 
formulations of drug delivery systems loaded with these compo-
nents [138]. For example, Hoffman et al., (2014) have devised pro-
nanolipospheres (PNLs) which consist of orally administrable com-
binations of lipids, surfactants and co-solvent loaded with piperine 
[139]. This kind of system would improve the bioavailability of 
drugs with poor pharmacokinetic properties i.e. achieving a reliable 
absorption of the drug from the GI tract. In the future, other drugs 
and herbal extracts encumbered by poor intestinal absorption due 
either to their low permeability or the fact that they are P-
glycoprotein substrates may be formulated with piperine i.e. piper-
ine can inhibit intestinal P-gp and thus facilitate the drug’s absorp-
tion. As an example, researchers recently developed a formulation 
to allow the oral delivery of drugs or herbal extracts with low solu-
bility/permeability after their complexation with piperine in a car-
bohydrate substrate solubilized with water, ethanol or an organic 
solvent [140]. This solution was water soluble and not a substrate of 
P-gp. Moreover, in the most recent studies, piperine has been used 
as a penetration enhancer, i.e. it elevated the flux rate of an active 
compound (capsaicin) in a transdermal delivery device [141]. 
 These promising results from the nano-formulations of piperine 
highlight the possibility that new drug delivery systems will be-
come available and piperine’s putative health benefits may be fully 
exploited. 
CONCLUSION 
 Today, there is no doubt that piperine, the most abundant com-
ponent in species of pepper, possesses optimal characteristics for 
inclusion into the broad nutraceutical family. Many studies have not 
only confirmed its antioxidant but also bioavailability enhancer 
properties for other antioxidants. As research on this topic continue 
to expand, new opportunities are opening. Progress is made in 
achieving a deeper understanding of piperine’s action, as well as in 
finding new ways to improve its bioavailability by incorporation 
into different carrier systems, mostly of a nano-sized nature. In 
conclusion, the interest in this compound is being redirected, it is no 
longer simply an interesting component from a well-known pungent 
spice, and instead, it should be considered as a new and important 
nutraceutical. 
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